T

The University of Sydney | Save Sight Institute

Research site

(Unclaimed)

Location

8 Macquarie Street Level 1 South Block, Sydney, New South Wales, Australia

Site insights

Top conditions

Top treatments

Lampalizumab

KIO-301

APL-2

Latanoprost

ranibizumab

Bevacizumab

Aflibercept

Xalatan

Parent organization

This site is a part of The University of Sydney

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 15 total trials

A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)

A phase I/II dose-escalating study of the safety, tolerability and efficacy of KIO-301 administered intravitreally to patients with retinitis pigment...

Enrolling

Choroideremia

Non-Syndromic Rod-Dominant Inherited Retinal Diseases

Drug: KIO-301

A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa (ABACUS-2)

The goal of the study is to investigate the safety, tolerability and efficacy of up to 3 doses of KIO-301 administered by intravitreal (IVT) injectio...

Enrolling

Retinitis Pigmentosa

Drug: 100 μg KIO-301

Drug: 50 μg KIO-301

Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration (i-SIGHT2)

The goal of this clinical trial is to characterize the safety and effectiveness of the i-Lumen AMD transpalpebral microcurrent device and therapy in...

Enrolling

Geographic Atrophy Secondary to Age-related Macular Degeneration

Intermediate AMD

Device: i-Lumen AMD